
Treatment is not chosen from the stage number alone: tumour size, lymph-node findings, distant spread, pathology and your general health all change the plan. By the end, you will know how treatment usually differs from stage 0 through stage IV, why surgery may come before or after drug treatment, and which test results guide each decision.
Key takeaways
- Stage describes tumour size, lymph nodes and distant spread.
- Pathology markers can change surgery, medicines and treatment timing.
- DCIS and early invasive cancer often begin with local treatment.
- Metastatic treatment targets tumour biology and is monitored over time.
What stages 0 through IV actually describe
Tumour size, lymph-node involvement and distant metastasis define anatomic stage: how large the breast tumour is, whether cancer has reached nearby nodes, and whether it has spread to organs or distant bones. Pathology and tumour biology then refine treatment; stage alone does not determine every drug or operation.
- Stage 0 is ductal carcinoma in situ (DCIS): abnormal cells remain inside a milk duct and have not invaded surrounding breast tissue. Treatment focuses on preventing invasive cancer, usually through local therapy.
- Stage I breast cancer is small invasive cancer with no involved nodes or limited nearby involvement. Treatment usually has curative intent, combining local treatment with systemic therapy when tumour biology and recurrence risk justify it.
- Stage II breast cancer includes larger tumours or greater lymph-node involvement without distant spread. Doctors may use surgery first or neoadjuvant therapy before surgery, while treatment remains aimed at cure.
- Stage III breast cancer involves extensive lymph-node disease, chest-wall or skin involvement, or inflammatory breast cancer. These regional breast cancer locales are treated with curative intent when the disease remains free of distant spread.
- Stage IV breast cancer means distant metastasis, such as cancer in bone, liver, lung or brain. Systemic treatment is the main approach, with the goal of managing a chronic controllable disease; surgery or radiation can relieve symptoms or protect a threatened organ but is not automatically curative.
Why pathology can change the treatment plan
A pathology report can redirect treatment even when the anatomic stage stays the same. ER status and PR status show whether tumour cells use hormones to grow. ER staining in at least 1% of tumour-cell nuclei is positive; ER-low positive means 1% to 10%, where endocrine responsiveness is less certain.
HER2 status determines HER2-directed treatment, while tumour grade indicates how abnormal and fast-growing the cells appear. Lymph-node findings, tumour size, menopausal status, general health and recurrence risk add context.
| Finding | Treatment implication | Key limitation |
|---|---|---|
| ER- or PR-positive | Endocrine therapy, such as tamoxifen or an aromatase inhibitor | Menopausal status affects drug choice; bone and clotting risks matter |
| HER2-positive | HER2-directed treatment, often with chemotherapy | Trastuzumab requires heart-function assessment |
| Triple-negative | Chemotherapy; immunotherapy for selected cancers | PD-L1 and treatment setting help determine eligibility |
| Hormone-receptor-positive, HER2-negative | A genomic assay can estimate chemotherapy benefit in selected early cancers | It does not replace pathology or apply universally |
| BRCA1 or BRCA2 mutation | A PARP inhibitor or another targeted treatment may be considered | Eligibility depends on stage, tumour subtype and prior treatment |
| Actionable metastatic finding | Targeted therapy eligibility may follow the detected alteration | Biopsy the metastasis when feasible because ER, PR or HER2 status can change |
Chemotherapy is not automatic after surgery. Genomic assay results, grade, nodes and biology help weigh its benefit, while ER-positive disease commonly receives endocrine therapy for at least five years. Residual HER2-positive or triple-negative disease after pre-surgery treatment can trigger additional postoperative therapy.
Treatment for DCIS and early invasive breast cancer
Ductal carcinoma in situ (DCIS) is stage 0: abnormal cells remain inside the ducts, but untreated DCIS can recur or become invasive. Stage I and selected stage II cancers are usually treated with curative intent, using surgery first when the tumour can be removed safely.
1. For DCIS, breast-conserving surgery (lumpectomy) removes the abnormal area. Radiation therapy is considered afterward, particularly when it lowers recurrence risk. Mastectomy is used when DCIS is extensive or affects multiple areas; radiation is not usually needed after complete mastectomy. Hormone-receptor-positive DCIS may also receive tamoxifen or an aromatase inhibitor such as anastrozole.
2. For invasive stage I or selected stage II disease, surgery commonly comes first. Lumpectomy is followed by whole-breast radiation therapy for most patients. Sentinel lymph-node biopsy checks spread to nearby nodes; axillary surgery is reserved for selected patients with greater nodal involvement or other findings.
3. Mastectomy may be chosen for a large tumour relative to breast size, multiple tumours, an inability to obtain clear margins, or personal preference. Post-mastectomy radiation is considered for substantial lymph-node involvement, a large tumour, involved margins, or inflammatory disease, not automatically for every patient.
4. Adjuvant treatment follows surgery when pathology shows added benefit. HER2-positive cancer usually receives chemotherapy plus HER2-directed therapy. Hormone-receptor-positive cancer may receive tamoxifen, or ovarian suppression with anastrozole, letrozole, or exemestane; postmenopausal patients may take an aromatase inhibitor alone. Selected patients also receive chemotherapy guided by tumour risk and genomic assay results.
When treatment starts before surgery in stage II, III or recurrent disease
A tumour that is operable does not always go straight to surgery. Neoadjuvant treatment, given beforehand, can shrink the breast tumour and involved lymph nodes, making surgery more effective or allowing breast-conserving surgery. It is commonly used for locally advanced breast cancer and many stage II–III HER2-positive or triple-negative breast cancer cases.
1. The drug plan follows tumour biology. HER2-positive disease often receives chemotherapy with trastuzumab; selected triple-negative breast cancer receives chemotherapy with pembrolizumab. Hormone-receptor-positive, HER2-negative disease may need chemotherapy, endocrine therapy, or both, based on pathology and estimated benefit.
2. Surgery provides a crucial test of response. The pathology report shows whether treatment eradicated invasive cancer or left residual disease in the breast or lymph nodes. Residual HER2-positive disease or residual triple-negative disease can lead to additional postoperative therapy rather than simply repeating the preoperative regimen.
3. The postoperative plan combines response, lymph-node findings and recurrence risk. A high tumour burden, positive nodes, involved margins, inflammatory breast cancer or a poor response can support chemotherapy, targeted therapy, endocrine therapy or post-mastectomy radiation. Small node-negative tumours with clear margins face a different radiation decision.
For recurrent breast cancer, doctors first establish whether the recurrence is local, regional or metastatic and reassess ER, PR and HER2 when feasible. Surgery may follow systemic treatment for a removable recurrence; adjuvant treatment afterward depends on the new pathology, previous therapies and the risk of another recurrence.
How metastatic breast cancer treatment is selected and monitored
A biopsy of metastasis is often recommended when it is safe and practical, because ER, PR, or HER2 results can differ from the original tumour. Treatment for metastatic breast cancer or unresectable recurrent disease then follows the current subtype, actionable mutations, previous treatment, symptoms, and your overall health—not stage alone.
- Hormone-receptor-positive/HER2-negative disease is often treated with endocrine therapy plus a CDK4/6 inhibitor; chemotherapy is reserved for particular patterns of progression or urgent organ-threatening disease.
- HER2-positive disease uses HER2-directed therapy, which may include trastuzumab with another targeted drug and chemotherapy. Heart-function assessment matters because trastuzumab-related treatment can affect cardiac function.
- Selected triple-negative cancers may receive immunotherapy, while an antibody-drug conjugate may be appropriate after defined prior treatments. HER2-low disease can qualify for a HER2-targeted antibody-drug conjugate, although HER2-low is not the same as HER2-positive disease.
Your oncologist monitors scans, examination findings, blood counts, liver and kidney tests, symptoms, and treatment toxicity. A scan alone does not decide success: stable disease with less pain and preserved function can justify continuing treatment, while progression or intolerable toxicity may require a change.
Specialist support helps compare expected benefit against neuropathy, fatigue, heart effects, fertility concerns, and time spent in treatment. Dr Avinash Talele-Best cancer specialist can help coordinate systemic therapy with palliative radiation for painful or threatening sites, symptom management, nutrition, and rehabilitation so treatment decisions reflect both tumour control and daily life.
Related services
Breast Cancers Breast cancer is cancer that forms in the cells of the breasts. After skin cancer, breast cancer is the most common cancer diagnosed in women. View service → |
Immunotherapy Immunotherapy 36 years old female presented with severe abdominal pain with jaundice with weakness being wheelchair bound.Her PETCT showed multiple liver... |
Frequently asked questions
What do breast cancer stages 0 through IV describe?
Stage describes tumour size, nearby lymph-node involvement and whether cancer has spread to distant organs or bones. Stage 0 refers to non-invasive disease, while stage IV indicates distant spread.
Why can pathology change the breast cancer treatment plan?
Pathology identifies tumour features such as hormone-receptor status, HER2 status, grade and other biological findings. These results help determine which medicines, surgery and treatment sequence fit the cancer.
How is DCIS treated compared with early invasive breast cancer?
DCIS is non-invasive and is treated with local surgery, with radiation or hormone therapy considered according to the individual case. Early invasive cancer may require breast surgery, lymph-node assessment and additional medicines.
When does treatment start before surgery for breast cancer?
Treatment before surgery, called neoadjuvant treatment, is used for selected stage II or III cancers and some recurrent cancers. The choice depends on tumour biology, size, lymph nodes and the planned operation.
How is metastatic breast cancer treatment selected and monitored?
Treatment for metastatic disease is selected using tumour biology, previous treatments, symptoms, overall health and the sites of spread. Doctors monitor symptoms, examination findings, scans and laboratory tests to assess benefit and adjust treatment.
Related services
Palliative Chemotherapy In the last stages of cancer when other treatment modalities are unsuccessful, we strive to provide a decent, pain-free quality of life with... View service → |
Chemotherapy Chemotherapy Chemotherapy is a group of drugs or medicines used to treat cancer. |
Physiotherapy Physiotherapy Our oncology-trained physiotherapists ensure physical fitness of patients during treatment, and post-treatment rehabilitation and help combat some... |
Targeted Therapy Attacking cancer cells more effectively with drugs, targeted therapy has has been found to be highly effective. View service → |






